The Institute for Innovation & Valuation in Health Care, InnoValHC, is an independent not-for-profit research organization.
The Institute was established in 2005 by a group of scientists with medical, health economic, and econometric backgrounds, as well as hands-on management experience. Today, the Institute and its projects are overseen by three of its founders (see People). The Institute's first major project was the health economic analysis of clinically proven treatment strategies for attention-deficit/hyperactivity disorder (ADHD) based upon the Multimodal Treatment of ADHD (MTA) Study, initiated by the National Institute of Mental Health (NIMH) in Bethesda, Maryland. While the Institute’s activities have retained a certain focus on the economics of attention disorders, the range of subjects studied has been growing continuously (see Purpose and Projects).
Today the areas of interest extend beyond traditional cost effectiveness and cost benefit analyses, encompassing both the normative foundations and the methods of health economic evaluations, Health Technology Assessments (HTAs) in theory and practice, health care utilization and cost studies (including budget impact analyses), as well as the identification, demonstration, measurement and communication of the clinical and economic value of “health technologies”, including the related issues of market access, pricing and reimbursement (for example, for diagnostics, medical devices, pharmaceutical products, and likewise institutional arrangements and processes of health care delivery).
From its inception, the Institute has been formally associated with the Ludwigshafen University of Applied Economic Sciences, through a cooperation agreement.
The Institute is a member of the Stockholm Network, the leading pan-European association of market-oriented think tanks.
The Institute is also a founding member of the Alliance for the Advancement of Applied Health Economics (A3HE).